Related Experiment Video
Updated: Aug 6, 2026
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
Genetic Cholestasis Syndromes
Eliza Flanagan1, Natassia Pinpin Tan1
1The Autoimmune and Rare Liver Disease Programme, University Health Network, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.
Clinics in Liver Disease
|July 22, 2026
Summary
Genetic cholestatic liver syndromes like PFIC are reviewed, focusing on genotype-phenotype links. Understanding molecular classification aids prognosis and treatment, including new therapies like ileal bile acid transport inhibitors.
Area of Science:
- Hepatology
- Genetics
- Molecular Biology
Background:
- Genetic cholestatic liver diseases are a diverse group of inherited disorders.
- Understanding genotype-phenotype correlations is crucial for managing these conditions.
- Progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis disorders, and cholangiopathies represent key examples.
Purpose of the Study:
- To review common genetic cholestatic liver syndromes.
- To explore genotype-phenotype correlations and their clinical implications.
- To discuss the role of molecular classification in prognosis, malignancy risk, and therapeutic response.
Main Methods:
- Literature review of genetic cholestatic liver syndromes.
- Analysis of genotype-phenotype data for PFIC, bile acid synthesis disorders, and cholangiopathies.
- Examination of current and emerging therapeutic strategies.
Main Results:
- Molecular classification provides insights into disease progression and outcomes.
- Specific genetic mutations correlate with distinct clinical presentations and severity.
- Emerging therapies, including ileal bile acid transport inhibitors, show promise.
Conclusions:
- Genotype-phenotype correlations are essential for personalized medicine in cholestatic liver diseases.
- Molecular classification guides prognostic assessment and treatment selection.
- Targeted therapies offer new hope for patients with conditions like PFIC and Alagille syndrome.
Related Concept Videos
01:20Cholecystitis
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:25Jaundice
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...